| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EURURO.2013.02.002 |
| P698 | PubMed publication ID | 23433805 |
| P50 | author | Mette Nørgaard | Q54605007 |
| P2093 | author name string | Michael Borre | |
| Christina G Jespersen | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| prostate cancer | Q181257 | ||
| P304 | page(s) | 704-709 | |
| P577 | publication date | 2013-02-12 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study | |
| P478 | volume | 65 |
| Q39273026 | A Cost-Utility Analysis of Prostate Cancer Screening in Australia. |
| Q86179569 | Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy |
| Q38261253 | Adverse effects of androgen-deprivation therapy in prostate cancer and their management |
| Q85240033 | Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies |
| Q86342949 | Androgen deprivation therapy for prostate cancer: friend or foe to the cardiovascular system? |
| Q43242594 | Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer |
| Q39247489 | Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease |
| Q40456917 | Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. |
| Q61807631 | Cancer-associated stroke: Pathophysiology, detection and management (Review) |
| Q92247502 | Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men |
| Q26801112 | Cardiovascular effects of hormone therapy for prostate cancer |
| Q38852165 | Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective |
| Q40797796 | Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists |
| Q38542600 | Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms |
| Q57109226 | Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer |
| Q96018468 | Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry |
| Q48167919 | Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology |
| Q38671819 | Current and future strategies for the nutritional management of cardiometabolic complications of androgen deprivation therapy for prostate cancer |
| Q38803264 | Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. |
| Q38619677 | Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review |
| Q62897972 | Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study |
| Q36714085 | Differences in Hypercholesterolemia and Atherogenesis Induced by Common Androgen Deprivation Therapies in Male Mice |
| Q41669642 | Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events |
| Q64108002 | Effect of Androgen Deprivation Therapy on Other-Cause of Mortality in Elderly Patients with Clinically Localized Prostate Cancer Treated with Modern Radiotherapy: Is There a Negative Impact? |
| Q42290613 | Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study |
| Q34415540 | Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study |
| Q51315511 | GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. |
| Q37063622 | Group-based exercise in daily clinical practice to improve physical fitness in men with prostate cancer undergoing androgen deprivation therapy: study protocol. |
| Q36490409 | Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel. |
| Q57108196 | Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach |
| Q92650848 | Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study |
| Q33819775 | Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate Cancer |
| Q38353835 | Management of metastatic hormone-sensitive prostate cancer |
| Q31111735 | Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study |
| Q47754588 | Metabolic changes in patients with prostate cancer during androgen deprivation therapy |
| Q37205661 | Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies |
| Q40164167 | No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. |
| Q38370997 | Pharmacologic androgen deprivation and cardiovascular disease risk factors: a systematic review. |
| Q51648451 | Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study. |
| Q91834228 | Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men |
| Q41339127 | Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong |
| Q49204760 | Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study |
| Q93112107 | Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy |
| Q28069320 | Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review |
| Q89751442 | Temporal Trends in the Prevalence of Cancer and Its Impact on Outcome in Patients With First Myocardial Infarction: A Nationwide Study |
| Q34134273 | Testosterone and weight loss: the evidence |
| Q40614195 | The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada |
| Q93046502 | The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study |
| Q43992393 | The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study |
| Q37708169 | The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer |
| Q88166486 | The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study |
| Q38817011 | The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. |
| Q35213928 | Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study |
| Q52854661 | [Cardiovascular risks of androgen deprivation therapy for prostate cancer]. |
Search more.